Market news

Paysign grew Q2 revenue 48.1% YoY to $28.3 million, raised 2026 guidance twice, and got plasma growing 21.4% after a flat 2025. Learn more about PAYS stock here.

Paysign (NASDAQ:PAYS) operates in two healthcare-focused businesses: payment services for plasma donors and pharmaceutical patient-affordability programs, Chief Financial Officer Jeff Baker said during a company presentation. Baker described the company as both a payments and life sciences business

Paysign (PAYS) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Paysign (PAYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The updated analyst work on Paysign now points to a higher implied fair value, with the modeled figure moving from US$10.45 to US$13.10. Bullish analysts link these higher targets to a stronger reaction to Paysign’s recent Q2 report, raised guidance and growing confidence in the company’s execution, including new pharma program wins. As you read on, you will see how these shifting targets fit into the broader narrative and what to watch as the story develops from here. Analyst Price Targets...

HENDERSON, Nev., August 18, 2026--Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced it will be presenting at the 17th Annual Midwest IDEAS Investor Conference to be held August 26-27, 2026 at the InterContinental in Chicago, Illinois.

Here is how Paysign, Inc. (PAYS) and Sezzle Inc. (SEZL) have performed compared to their sector so far this year.

PaySign (PAYS) has an average rating of buy and mean price target of $13.10, according to analysts p

Mark Newcomer, 10% Owner, Director, Chief Executive Officer, on August 06, 2026, sold 150,000 shares

HENDERSON, Nev., August 05, 2026--Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive pharma patient affordability offerings, financial technology products and integrated payment processing, today announced financial results for the second quarter 2026.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

HENDERSON, Nev., July 14, 2026--Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, will discuss second quarter 2026 earnings at 5:00 p.m. Eastern time on Wednesday, August 5, 2026.

Detailed price information for Minebea CO Ltd Ord (MNBEF) from The Globe and Mail including charting and trades.